克洛扎的剂量模式和治疗耐药精神分裂症患者的临床结果
Sherry Kit Wa Chan1, Yi Nam Suen2, Wai Ching Yan3
1Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China.
概括
较低剂量的克洛扎宾 (≤300 mg/天) 在治疗耐药精神分裂症 (TRS) 患者中显著改善了认知功能. 单一疗法还增强了动机和职业功能,指导了针对TRS的最优化克洛扎宾处方.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 克洛扎是治疗耐药性精神分裂症谱系障碍 (TRS) 的唯一有效治疗方法.
- 克洛扎的处方模式可以影响患者的治疗结果.
- 了解最佳的克洛沙平使用对于管理TRS至关重要.
研究的目的:
- 研究克洛扎宾剂量频率,剂量水平和增加对TRS患者临床,社会和认知结果的影响.
- 探索克洛扎宾处方模式和患者结果之间的相互作用.
- 在现实环境中为优化克洛扎宾治疗提供指导.
主要方法:
- 采访了124名接受克洛扎宾TRS治疗的患者.
- 分析了剂量频率 (每日单剂量与多剂量),剂量水平 (≤300 mg/天与>300 mg/天),单疗法与增强疗法.
- 协差分析 (ANOVA) 用于检查处方模式对结果的影响.
主要成果:
- 服用较低剂量的克洛扎宾 (LD,≤300毫克/天) 的患者表现出明显改善的认知功能.
- 单疗法 (MT) 与更好的动机和职业功能有关,特别是在高剂量组 (HD,>300 mg/天).
- 总体而言,没有观察到剂量频率的显著影响,但多次每日剂量 (MDD) 在LD组内显示出处理速度和记忆的好处.
结论:
- 较低的克洛沙平剂量 (≤300毫克/天) 与TRS患者的认知结果改善有关.
- 克洛扎单一治疗可能会增强动机和职业功能.
- 这些发现为优化克洛扎宾处方策略提供了指导,以改善TRS患者的社会和认知结果.
相关概念视频
Psychosis: Goals of Pharmacotherapy
166
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
166
Psychosis and Antipsychotic Drugs: Overview
328
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
328
Drug Therapy
69
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
69
Antipsychotic Drugs: Typical and Atypical Agents
249
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
249
Antipsychotic Drugs: Therapeutic Uses and Side Effects
261
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
261
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
197
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
197


